Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs SEC filings (Ticker: RVPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reviva Pharmaceuticals Holdings, Inc. filings document a Nasdaq-listed biopharmaceutical issuer developing drug candidates for CNS, inflammatory and cardiometabolic diseases. Its 8-K reports furnish operating and financial results, Regulation FD updates, and material-event disclosures tied to the brilaroxazine schizophrenia program, intellectual-property strategy, public offerings, and capital structure.
Proxy and other filings cover shareholder voting matters, director elections, auditor ratification, executive compensation, authorized share amendments, certificate amendments, security-holder rights, and Nasdaq listing-compliance notices. The filings also identify the company's common stock under symbol RVPH and describe common-stock, warrant and governance disclosures relevant to its public-company reporting.
Reviva Pharmaceuticals (Nasdaq: RVPH) entered into a $10 million registered public offering of 20 million common shares paired with 20 million five-year Series C warrants and 20 million one-year Series D warrants, all priced at $0.50 per unit.
Net proceeds of roughly $9 million will fund R&D, working capital and general corporate purposes. The warrants are immediately exercisable at $0.50, include 4.99%/9.99% ownership caps and Black-Scholes cash-out rights on fundamental transactions. Closing is expected 27 Jun 2025, subject to customary conditions, and the company agreed to 60-day lock-up on most new issuances and a 12-month restriction on variable-rate financings.
- Placement Agent: A.G.P./Alliance Global Partners—7% cash fee on most proceeds.
- Registration: effective S-3 (No. 333-276848), prospectus supplement filed.
- Use of proceeds focused on pipeline advancement.
Reviva Pharmaceuticals has announced a public offering of 20,000,000 shares of common stock at $0.50 per share, along with Series C and Series D Common Warrants. The total offering value is $10 million, with expected net proceeds of $9.3 million before expenses.
Key offering details:
- Each share comes with two warrants: one Series C warrant (5-year term) and one Series D warrant (12-month term)
- Both warrant series have an exercise price of $0.50 per share
- A.G.P./Alliance Global Partners serving as sole Placement Agent, receiving 7% fee (3.5% for certain investors)
- No minimum offering requirement or escrow arrangement
- Expected closing date: June 27, 2025
The offering represents a significant discount to the last reported share price of $0.8049 on Nasdaq (RVPH). The company notes it is a "smaller reporting company" and warns investors of potential risks, including limited warrant liquidity as no trading market exists or is planned for the warrants.
Reviva Pharmaceuticals Holdings has announced a new securities offering including shares of common stock, Series C and D Common Warrants, and Pre-Funded Warrants. The offering includes:
- Common stock (at $0.8049 per share last trading price) with accompanying warrants
- Series C Common Warrants with 5-year expiration and immediate exercisability
- Series D Common Warrants with 12-month expiration and immediate exercisability
- Pre-Funded Warrants for investors who would exceed 4.99% (or 9.99%) ownership
Key Details: A.G.P./Alliance Global Partners is serving as sole Placement Agent, receiving a 7% fee (3.5% for certain investors). The offering has no minimum requirement and will terminate by June 2025 unless completed sooner. Trading under symbol RVPH on Nasdaq Capital Market, the company qualifies as a "smaller reporting company." Proceeds will be immediately available for company use, though total offering amount remains undetermined.